KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Net Cash Flow (2020 - 2025)

Ginkgo Bioworks Holdings' Net Cash Flow history spans 6 years, with the latest figure at $55.6 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 199.71% year-over-year to $55.6 million; the TTM value through Dec 2025 reached -$393.6 million, down 2.61%, while the annual FY2025 figure was -$393.6 million, 2.61% down from the prior year.
  • Net Cash Flow reached $55.6 million in Q4 2025 per DNA's latest filing, up from -$94.5 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $1.5 billion in Q3 2021 to a low of -$250.4 million in Q1 2025.
  • Average Net Cash Flow over 5 years is -$8.7 million, with a median of -$90.3 million recorded in 2023.
  • Peak YoY movement for Net Cash Flow: tumbled 557.67% in 2023, then skyrocketed 199.71% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$172.4 million in 2021, then soared by 113.33% to $23.0 million in 2022, then crashed by 557.67% to -$105.1 million in 2023, then surged by 47.0% to -$55.7 million in 2024, then surged by 199.71% to $55.6 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's Net Cash Flow are $55.6 million (Q4 2025), -$94.5 million (Q3 2025), and -$104.2 million (Q2 2025).